Indaptus Therapeutics, Inc., a clinical biotechnology company, develops various anti-cancer and anti-viral immunotherapy products. Its lead clinical candidate is Decoy20 used to produce single agent activity and/or combination therapy-based durable responses of lymphoma, hepatocellular, colorectal, and pancreatic tumors, as well as chronic hepatitis B virus and human immunodeficiency virus infection, which is in Phase 2 clinical trial. The company was formerly known as Intec Parent, Inc. and changed its name to Indaptus Therapeutics, Inc. in August 2021. Indaptus Therapeutics, Inc. is headquartered in New York, New York.
Indaptus Therapeutics, Inc. Frequently Asked Questions
What is the ticker symbol for Indaptus Therapeutics, Inc.? What does INDP stand for in stocks?
INDP is the stock ticker symbol of Indaptus Therapeutics, Inc.. Every public company that trades on a stock exchange gets a ticker symbol.
What is the market capital of Indaptus Therapeutics, Inc. (INDP)?
As of Fri Dec 20 2024, market cap of Indaptus Therapeutics, Inc. is 9.59 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.
What is the fair value of INDP stock?
You can check INDP's fair value in chart for subscribers.
Is Indaptus Therapeutics, Inc. a good stock to buy?
The fair value guage provides a quick view whether INDP is over valued or under valued. Whether Indaptus Therapeutics, Inc. is cheap or expensive depends on the assumptions which impact Indaptus Therapeutics, Inc.'s fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for INDP.